Department of Radiation Oncology, University Hospital Wuerzburg, Josef-Schneider-Str. 11, 97080, Wuerzburg, Germany.
Department of Internal Medicine, Leopoldina Hospital Schweinfurt, Schweinfurt, Germany.
Sci Rep. 2022 Nov 17;12(1):19730. doi: 10.1038/s41598-022-24192-8.
This retrospective, single-institutional study investigated long-term outcome, toxicity and health-related quality of life (HRQoL) in meningioma patients after radiotherapy. We analyzed the data of 119 patients who received radiotherapy at our department from 1997 to 2014 for intracranial WHO grade I-III meningioma. Fractionated stereotactic radiotherapy (FSRT), intensity modulated radiotherapy (IMRT) or radiosurgery radiation was applied. The EORTC QLQ-C30 and QLQ-BN20 questionnaires were completed for assessment of HRQoL. Overall survival (OS) for the entire study group was 89.6% at 5 years and 75.9% at 10 years. Local control (LC) at 5 and 10 years was 82.4% and 73.4%, respectively. Local recurrence was observed in 22 patients (18.5%). Higher grade acute and chronic toxicities were observed in seven patients (5.9%) and five patients (4.2%), respectively. Global health status was rated with a mean of 59.9 points (SD 22.3) on QLQ-C30. In conclusion, radiotherapy resulted in very good long-term survival and tumor control rates with low rates of severe toxicities but with a deterioration of long-term HRQoL.
本回顾性单中心研究调查了接受放疗的脑膜瘤患者的长期疗效、毒性和健康相关生活质量（HRQoL）。我们分析了 1997 年至 2014 年在我科接受放疗的 119 例颅内 WHO 分级 I-III 脑膜瘤患者的数据。采用分次立体定向放疗（FSRT）、调强放疗（IMRT）或放射外科放疗。使用 EORTC QLQ-C30 和 QLQ-BN20 问卷评估 HRQoL。整个研究组的总生存率（OS）在 5 年时为 89.6%，在 10 年时为 75.9%。5 年和 10 年时的局部控制率（LC）分别为 82.4%和 73.4%。22 例（18.5%）患者出现局部复发。7 例（5.9%）和 5 例（4.2%）患者出现较高分级的急性和慢性毒性反应。QLQ-C30 的全球健康状况平均评分为 59.9 分（标准差 22.3）。总之，放疗可获得非常好的长期生存率和肿瘤控制率，毒性反应发生率低，但长期 HRQoL 恶化。
Zotero 插件